PROGRESS IN DRUG DISCOVERY

Novel in vitro cell models for improved compound & target research
SIRION BIOTECH specializes in viral vector platforms and provides sophisticated cell modeling. This enables much improved target identification and compound screening in the drug, the food & cosmetic industries. It also allows for much better chances to succeed with primary cell immortalizations. SIRION BIOTECH is able to construct adenovirus serotype vectors serving as the basis for novel future vaccines with much improved immunity.

SIRION BIOTECH is a technology driven company

- Viral Vectors AV, LV and AAV
- RNAiONE™

Sophisticated Technology Platform

- 3D cell culture
- Novel adenovirus serotypes for vaccination
- Primary cell immortalization

Cells by Design

- Customized in vitro cell models
- SenCELL™ cell lines with built-in reporter genes, e.g. Hypoxia, sensory taste cells

Partnering/Outlicensing
how to work with SIRION BIOTECH

Joint development at cost plus and milestones Royalty agreement

In vitro cell models
- Exclusive rights on single clones

Fee for Service Master Service Agreement
- Custom viruses
- shRNA validation

• Tailor made cell models
• Immortalization service
• 3D cell models

• New in vitro systems
• New AV serotypes

faster reliable predictive cost saving

SIRION BIOTECH
SIRION BIOTECH was founded in 2006 by scientists from Munich University (LMU). The idea was to change the paradigm of in vitro cell modelling for more effective target & compound research. Since then, SIRION BIOTECH has been filing several patent applications and has been refining its technical competence in hundreds of client projects. Clients and Alliance Partners are mostly from industry in Europe, Japan and USA.